Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men

Completed · Not applicable

Conditions studied: Healthy Volunteers

In brief

The purpose of this trial is to examine the short-term effects of Growth Hormone Releasing Hormone (GHRH, tesamorelin) administration in healthy men. We hypothesize that GHRH will increase GH pulse height and will not affect insulin sensitivity.

Key facts

Study ID

NCT00850564

Run by

Massachusetts General Hospital

People needed

15

Starts

2009-02-01

Expected to finish

2010-04-01

Last updated by the study team

2011-04-19

Who can join

Age: 18 and older, up to 60. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Men aged 18-60 years
• BMI > 20kg/m2 and <35kg/m2

You may not qualify if…

• Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study
• Use of GH or growth hormone stimulating peptides within six months of starting the study
• Change in lipid lowering or antihypertensive regimen within 3 months of screening
• Fasting blood sugar > 126 mg/dL, SGOT > 2.5 times ULN, Hgb < 12.0 g/dL, creatinine > 1.4 mg/dL
• Carpal tunnel syndrome
• Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer
• For men, history of prostate cancer or evidence of prostate malignancy by PSA > 5 ng/mL
• Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis
• Weight < 110 lbs.

Where it is running

• MGH — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.